Clinical trial
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute…
NCT00271063 · Callisto Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00271063 |
|---|---|
| Title | Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia |
| Official title | Phase I/II Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia |
| Lead sponsor | Callisto Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Liposomal Annamycin |
| Enrollment | 34 |
| Start date | Oct 1, 2005 |
| Completion | Apr 1, 2008 |
| First posted | Dec 30, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: